Michael E. Rome - 13 Jun 2022 Form 4 Insider Report for Kinnate Biopharma Inc.

Role
Director
Signature
/s/ Mark A. Meltz, as attorney-in-fact
Issuer symbol
N/A
Transactions as of
13 Jun 2022
Net transactions value
$0
Form type
4
Filing time
15 Jun 2022, 17:00:29 UTC
Previous filing
06 Oct 2021
Next filing
05 Apr 2024
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KNTE Stock Option (right to buy) Award $0 +20,250 $0.000000 20,250 13 Jun 2022 Common Stock 20,250 $8.38 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 1/12th of the shares underlying the Option vest and become exercisable on a monthly basis starting July 13, 2022 (the Vest Base Date) and thereafter on the same day of the month as the Vest Base Date or if earlier, the day immediately before the date of the next Annual Meeting of Stockholders that occurs after the Vest Base Date.